Telomir Pharmaceuticals Inc
NASDAQ:TELO
Income Statement
Earnings Waterfall
Telomir Pharmaceuticals Inc
Income Statement
Telomir Pharmaceuticals Inc
| Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||
| Interest Expense |
0
|
0
|
0
|
1
|
2
|
6
|
0
|
0
|
4
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||
| Operating Expenses |
(1)
|
(1)
|
(3)
|
(3)
|
(4)
|
(13)
|
(15)
|
(20)
|
(12)
|
(14)
|
(16)
|
(11)
|
|
| Selling, General & Administrative |
(0)
|
(0)
|
(1)
|
(2)
|
(2)
|
(3)
|
(5)
|
(9)
|
(9)
|
(12)
|
(15)
|
(10)
|
|
| Research & Development |
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(2)
|
(3)
|
(1)
|
(1)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
(7)
|
(7)
|
(7)
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(1)
N/A
|
(1)
-49%
|
(3)
-106%
|
(3)
-27%
|
(4)
-18%
|
(13)
-226%
|
(15)
-15%
|
(20)
-34%
|
(12)
+41%
|
(14)
-24%
|
(16)
-12%
|
(11)
+30%
|
|
| Pre-Tax Income | |||||||||||||
| Interest Income Expense |
0
|
0
|
(0)
|
(1)
|
(2)
|
(6)
|
(10)
|
(9)
|
(4)
|
(4)
|
0
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
(7)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(1)
N/A
|
(1)
-49%
|
(3)
-116%
|
(4)
-54%
|
(13)
-209%
|
(19)
-44%
|
(25)
-32%
|
(29)
-17%
|
(17)
+43%
|
(19)
-13%
|
(16)
+14%
|
(11)
+30%
|
|
| Net Income | |||||||||||||
| Income from Continuing Operations |
(1)
|
(1)
|
(3)
|
(4)
|
(13)
|
(19)
|
(25)
|
(29)
|
(17)
|
(19)
|
(16)
|
(11)
|
|
| Net Income (Common) |
(1)
N/A
|
(1)
-49%
|
(3)
-116%
|
(4)
-54%
|
(13)
-209%
|
(19)
-44%
|
(25)
-32%
|
(29)
-17%
|
(17)
+43%
|
(19)
-13%
|
(16)
+14%
|
(11)
+30%
|
|
| EPS (Diluted) |
-0.03
N/A
|
-0.05
-67%
|
-0.1
-100%
|
-0.15
-50%
|
-0.48
-220%
|
-0.69
-44%
|
-0.84
-22%
|
-0.98
-17%
|
-0.56
+43%
|
-0.63
-12%
|
-0.54
+14%
|
-0.34
+37%
|
|